Sugi Predict

Sugi Predict / Targets / CYP2W1

CYP2W1

Cytochrome P450 2W1 · Q8TAV3 · CYP2W1 on Sugi Atlas →

6,402 patent compounds predicted against CYP2W1, 4,073 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2954516 SCHEMBL2954516 0.70 3/20
SCHEMBL2753072 SCHEMBL2753072 0.56 3/20
SCHEMBL2752346 SCHEMBL2752346 0.52 3/20
SCHEMBL2752131 SCHEMBL2752131 0.52 3/20
SCHEMBL1165314 SCHEMBL1165314 0.47 3/20
SCHEMBL971260 SCHEMBL971260 0.42 3/20
SCHEMBL2749440 SCHEMBL2749440 0.42 3/20
SCHEMBL2752725 SCHEMBL2752725 0.41 3/20
SCHEMBL2091704 SCHEMBL2091704 0.41 3/20
SCHEMBL971261 SCHEMBL971261 0.40 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2566375) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592428) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2570005) 0.89 2/20
SCHEMBL2584612 SCHEMBL2584612 0.79 2/20
SCHEMBL2407878 SCHEMBL2407878 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
SCHEMBL2580241 SCHEMBL2580241 0.72 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592437) 0.70 2/20
SCHEMBL2582318 SCHEMBL2582318 0.68 2/20
SCHEMBL1180429 SCHEMBL1180429 0.67 2/20

Clinical trials — most relevant to CYP2W1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Herb-Opioid Interactions PHASE4COMPLETED
Comparative Effects of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes PHASE4COMPLETED
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. PHASE1/PHASE2RECRUITING
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer PHASE2COMPLETED
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis PHASE2ACTIVE_NOT_RECRUITING
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer PHASE1COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma PHASE1COMPLETED
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers PHASE1COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers PHASE1COMPLETED
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants PHASE1COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease PHASE1COMPLETED
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy nanUNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting. nanCOMPLETED
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen nanUNKNOWN
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Connecting Breath and Mind for CYP With Long COVID nanUNKNOWN
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk nanCOMPLETED
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics nanCOMPLETED
Cyclophosphamide in Lupus Nephritis nanUNKNOWN
Effects of Genotype on CYP2C9 Drug Interactions nanCOMPLETED
Pharmacogenomic Profiling of Pediatric Patients nanCOMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis nanCOMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers nanCOMPLETED
Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP2W1 binder may also engage these)

ProteinNameSimilarity
E9Q816 — 0.999 E9Q816 →
CYP2S1 Cytochrome P450 2S1 (EC 1.14.14.-) (CYPIIS1) 0.992 landscape →
Q9DBX6 — 0.989 Q9DBX6 →
Q29488 — 0.984 Q29488 →
CYP2D6 Cytochrome P450 2D6 0.984 landscape →
A0A087X1C5 — 0.982 A0A087X1C5 →
Q2XNC8 — 0.981 Q2XNC8 →
O18992 — 0.978 O18992 →
Q2XNC9 — 0.978 Q2XNC9 →
Q2LCM1 — 0.976 Q2LCM1 →
Q8WNW0 — 0.974 Q8WNW0 →
Q29473 — 0.973 Q29473 →
P15540 — 0.971 P15540 →
P00191 — 0.971 P00191 →
O46658 — 0.971 O46658 →
Q01361 — 0.970 Q01361 →
Q64403 — 0.969 Q64403 →
Q2LA60 — 0.967 Q2LA60 →
Q64680 — 0.967 Q64680 →
Q2LA59 — 0.967 Q2LA59 →
P12394 — 0.964 P12394 →
CYP27B1 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial 0.964 landscape →
Q9QUJ1 — 0.962 Q9QUJ1 →
CYP21A2 Steroid 21-hydroxylase 0.960 landscape →
Q9QYG5 — 0.957 Q9QYG5 →
P10633 — 0.954 P10633 →
Q49HH9 — 0.953 Q49HH9 →
O35132 — 0.953 O35132 →
P11714 — 0.952 P11714 →
O35084 — 0.952 O35084 →